Collegium Pharmaceutical (NASDAQ:COLL) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research report report published on Saturday morning.

A number of other research analysts also recently issued reports on COLL. Needham & Company LLC cut their price target on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Barclays cut their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $41.60 on Friday. The company has a market capitalization of $1.32 billion, a P/E ratio of 24.33 and a beta of 0.67. The company’s 50-day simple moving average is $46.36 and its two-hundred day simple moving average is $42.12. Collegium Pharmaceutical has a one year low of $23.23 and a one year high of $50.79. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. During the same quarter in the previous year, the business earned $1.77 earnings per share. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity at Collegium Pharmaceutical

In related news, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This represents a 6.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares in the company, valued at $4,991,038.21. This trade represents a 14.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of COLL. Janus Henderson Group PLC raised its position in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after purchasing an additional 518,721 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the period. Assenagon Asset Management S.A. boosted its stake in Collegium Pharmaceutical by 161.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after buying an additional 316,109 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Collegium Pharmaceutical by 897.2% during the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after purchasing an additional 242,310 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.